Loxbridge with Nobel Prize Winner to Combat Superbugs

Loxbridge Research signed a joint venture agreement to form Altermune Technologies to develop new therapeutics targeting combat resistant pathogens.

Loxbridge Research has entered a joint venture with Nobel Prize winner Dr Kary Mullis to develop therapeutics that combat antibiotic-resistant bugs. The joint venture has formed Altermune Technologies to treat resistant pathogens like MRSA, C. difficile, Pseudomonas, and pandemic influenza.

Loxbridge will provide a seed-funding package worth $7m, offering a revolution in anti-pathogen therapy - a space that has lacked the investment and innovation necessary to combat multi-drug resistant strains in recent years, the company said in a statement.

The Altermune method is designed to re-task antibodies already present in the body that are not ordinarily tasked to fight infections. The thera